Lithium Side Effects in the Medically Ill

1993 ◽  
Vol 23 (4) ◽  
pp. 357-382 ◽  
Author(s):  
W. Alexander Morton ◽  
Susan C. Sonne ◽  
R. Bruce Lydiard

Objective: This review will include the general pharmacology of lithium and discuss its effects on various organ systems, with emphasis on the medically ill patient as well as the geriatric patient with multiple medical problems. Methods: A full literature review on the side effects of lithium was performed. Attention is focused on the medically ill and possible drug interactions. Results: This review points to the numerous problems which can result in toxicity in the medically ill or the geriatric patient. Conclusion: Serious side effects can be avoided with proper drug monitoring and knowledge of potential drug interactions.

2014 ◽  
Vol 21 (4) ◽  
pp. 216-221 ◽  
Author(s):  
Aygin Bayraktar-Ekincioglu ◽  
Kutay Demirkan ◽  
Burcu Keskin ◽  
Oktay Aslantas ◽  
Evren Ozdemir

2020 ◽  
Author(s):  
Irfan Aygün ◽  
Mehmet Kaya ◽  
Reda Alhajj

Abstract To increase the success in Covid 19 treatment, many drug suggestions are presented, and some clinical studies are shared in the literature. There have been some attempts to use some of these drugs in combination. However, using more than one drug together may cause serious side effects on patients. Therefore, detecting drug-drug interactions of the drugs used will be of great importance in the treatment of Covid 19. In this study, the interactions of 8 drugs used for Covid 19 treatment with 645 different drugs and possible side effects estimates have been produced using Graph Convolutional Networks. Organ systems and diseases in which these 8 drugs cause the most negative effects have been identified. In addition, as it is known that some of these 8 drugs are used together in Covid-19 treatment, the side effects caused by using these drugs together are shared. With the experimental results obtained, it is aimed to facilitate the selection of the drugs and increase the success of Covid 19 treatment according to the targeted patient.


2014 ◽  
Vol 1 (2) ◽  
pp. 116-120
Author(s):  
Houari Toumi ◽  
◽  
Fatima Boudia ◽  
Fatima Zohra Nadjet Mekaouche ◽  
Habiba Fetati ◽  
...  

The risk of drug interactions in patients increases with the increasing number of drugs in the therapeutic regimens. To avoid or reduce them, management of these interactions is imperative. This management is to identify potential drug interactions by using the appropriate resources, to judge the clinical relevance, and to act accordingly with the prescriber. This article discusses the levels of severity of drug interactions and highlights the need for their management by presenting a part of the experience of the department of Pharmacovigilance EHU Oran. The intervention of the pharmacologist turns out beneficial by helping the clinician to manage risk associations in favor of better therapeutic efficacy and minimal side effects.


Author(s):  
Adetola Olaniyi Bojuwoye ◽  
Fatima Suleman ◽  
Velisha Ann Perumal-Pillay

Abstract Background Polypharmacy is the administration of an excessive number of medicines and a significant irrational medicine use practice. Little is known about this practice in South Africa. This study aimed to determine the level of polypharmacy and potential drug–drug interactions amongst the geriatric patient population in a facility in South Africa. Method A cross-sectional retrospective prescription chart review for 250 geriatric patients was conducted at the outpatient pharmacy department of a regional hospital. Variables extracted included demographic information, diagnosis, type of prescriber contact, and polypharmacy. Potential drug–drug interactions were determined with web-based multi-drug interaction checkers. Results The average (SD) number of diagnosed clinical problems was 3.54 ± 1.26, with hypertension, diabetes mellitus, and heart disease occurring most frequently. The level of polypharmacy was high with patients receiving an average (SD) of 12.13 ± 4.25 prescribed medicines from 3032 prescribed medicines. The level of polypharmacy was highest within the age categories, 60–64, and 70–74 years of age, respectively. The level of potential drug–drug interactions was also high with an average (SD) of 10.30 ± 7.48 from 2570 potential drug interactions. The majority of these interactions were moderate (72.5%) and pharmacodynamic (73.2%) by nature of the clinical severity of action and mechanism of action, respectively. Polypharmacy and type of prescriber contact were statistically significant contributors to the occurrence of potential drug–drug interactions, (F (2, 249) = 68.057, p < 0.05). However, in a multivariate analysis of variables to determine the strength of the association, polypharmacy was determined to be the strongest contributor to the occurrence of potential drug–drug interactions (p < 0.05) when compared with the type of prescriber contact (p value = 0.467). Therefore, irrespective of the type of prescriber contact, polypharmacy increases the potential for drug interactions among the sampled patient population. Conclusion A comprehensive consideration of disease management guidelines, patient factors, and rational medicine review could be measurable strategies towards improving medicine use. This would also limit the occurrence of significant drug interactions among the geriatric patient population. A national study is required to determine if differences occur across hospitals and regions.


2008 ◽  
Vol 12 (6) ◽  
pp. 255-267 ◽  
Author(s):  
Rahul Shukla ◽  
Denis Sasseville

Background: The management of psychodermatologic disease often involves the use of psychotropics by dermatologists. A general approach to the psychopharmacologic management of psychodermatological disease may be of assistance to the dermatologist. Objective: We review and provide a current psychopharmacologically based approach to management of common psychopathologies associated with psychodermatologic disorders, common side effects, and potential drug interactions that may occur with selected psychotropics. Methods: Using relevant MeSH terms, we performed a review of the literature from 1980 to 2006. Results and Conclusions: Effective psychopharmacologic management of psychodermatologic disease involves identifying and basing treatment on the associated psychopathology; familiarity with a variety of psychotropic agents, including antidepressants, anxiolytics, and antipsychotics; and the involvement of a psychiatrist when possible.


2006 ◽  
Vol 36 (4) ◽  
pp. 8
Author(s):  
ELIZABETH MECHCATIE

2018 ◽  
Vol 25 (21) ◽  
pp. 2503-2519 ◽  
Author(s):  
Anne Kokel ◽  
Marianna Torok

Background: Since the first isolation of antimicrobial peptides (AMPs) they have attracted extensive interest in medicinal chemistry. However, only a few AMP-based drugs are currently available on the market. Despite their effectiveness, biodegradability, and versatile mode of action that is less likely to induce resistance compared to conventional antibiotics, AMPs suffer from major issues that need to be addressed to broaden their use. Notably, AMPs can lack selectivity leading to side effects and cytotoxicity, and also exhibit in vivo instability. Several strategies are being actively considered to overcome the limitations that restrain the success of AMPs. Methods: In the current work, recent strategies reported for improving AMPs in the context of drug design and delivery were surveyed, and also their possible impact on patients and the environment was assessed. Results: As a major advantage AMPs possess an easily tunable skeleton offering opportunities to improve their properties. Strategic structural modifications and the beneficial properties of cyclic or branched AMPs in term of stability have been reported. The conjugation of AMPs with nanoparticles has also been explored to increase their in vivo stability. Other techniques such as the coupling of AMPs with specific antibodies aim to increase the selectivity of the potential drug towards the target. These strategies were evaluated for their effect on the environment highlighting green technologies. Conclusion: Although further research is needed taking into account both environmental and human health consequences of novel AMPs, several of these compounds are promising drug candidates for use in sustainable medicine.


Sign in / Sign up

Export Citation Format

Share Document